Drug Trial Radar · NCT00123474
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
Last checked: Nov 19, 2026Latest source record: Aug 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
724
Actual
Start
Jul 2005
Primary completion
Sep 2006
Study completion Jul 2014
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 25, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III study of BMS-354825 in subjects with chronic phase Philadelphia chromosome or BCR-ABL positive chronic myelogenous leukemia, who are resistant or intolerant to imatinib mesylate (Gleevec).
Conditions
- Myeloid Leukemia, Chronic, Chronic-Phase
Interventions
dasatinibDrug
Tablets, Oral, 50 mg BID, indefinitely, survival study
dasatinibDrug
Tablets, Oral, 70 mg BID, indefinitely, survival study
dasatinibDrug
Tablets, Oral, 100 mg QD, indefinitely, survival study
dasatinibDrug
Tablets, Oral, 140 mg QD, indefinitely, survival study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-UpTime frame: 6 months
Locations
137 sites in 31 countries. Site status is shown where the registry gives one.
University Of Alabama At Birmingham
Birmingham, Alabama
Central Hematology Oncology Medical Group Inc.
Alhambra, California
Pacific Cancer Medical Center Inc
Anaheim, California
Loma Linda University Cancer Center
Loma Linda, California
Pacific Shores Medical Group
Long Beach, California
Ucla Dept. Of Medicine
Los Angeles, California
Ventura County Hematology-Oncology Specialists
Oxnard, California
Kaiser Permanente Medical Center
Vallejo, California
Georgetown University Med Ctr
Washington D.C., District of Columbia
Washington Cancer Institute At Washington Hospital Center
Washington D.C., District of Columbia
University Of Florida
Gainesville, Florida
University Of Miami
Miami, Florida
Md Anderson Cancer Center Orlando
Orlando, Florida
Emory University School Of Medicine
Atlanta, Georgia
Georgia Cancer Specialists
Atlanta, Georgia
Gwinnett Hospital System Inc.
Lawrenceville, Georgia
Northwestern University Feinberg School Of Medicine
Chicago, Illinois
University Of Chicago
Chicago, Illinois
Oncology Hematology Associates Of Central Illinois, Pc
Peoria, Illinois
Indiana University Cancer Center
Indianapolis, Indiana
University Of Kansas Medical Center
Westwood, Kansas
University Of Kentucky
Lexington, Kentucky
University Of Maryland
Baltimore, Maryland
Dana Faber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Washington University School Of Medicine
St Louis, Missouri
Nebraska Methodist Hospital
Omaha, Nebraska
Devetten, Marcel
Omaha, Nebraska
Nevada Cancer Institute
Las Vegas, Nevada
The Cancer Center At Hackensack University Medical Center
Hackensack, New Jersey
The Cancer Institute Of New Jersey
New Brunswick, New Jersey
New York Presbyterian Hospital
New York, New York
University Of North Carolina At Chapel Hill
Chapel Hill, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
Oregon Health & Science University
Portland, Oregon
Western Pennsylvania Cancer Institute
Pittsburgh, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
Ut Southwestern Medical Center
Dallas, Texas
The University Of Texas Md Anderson Cancer Center
Houston, Texas
Seattle Cancer Care Alliance
Seattle, Washington
Showing 40 of 137 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.